Journal of Clinical Psychiatry

Subject Index to Volume 55: January 1994 Through December 1994

Academic Highlights
Beyond efficacy: setting standards in the treatment of depression. June 270–277
Buspirone: seven-year update. May 222–229
Depression in the elderly: clinical considerations and therapeutic approaches. Apr 166–173
Focus on SSRIs: broadening the spectrum of clinical use. Oct 459–466
International advances in the treatment of social phobia. Mar 123–129
Practical approaches to the treatment of social phobia. Aug 367–374
Social phobia: outlook for the '90s. Nov 503–510

Adolescents
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97

Affective Disorders
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. Banov, July 295–300
Concurrent use of clozapine and valproate in affective and psychotic disorders. Kando, June 255–257

Aggression
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Open trial of sertraline in personality disordered patients with impulsive aggression. Kavoussi, Apr 137–141
Use of clozapine in a mentally retarded and aggressive population. Cohen, Oct 440–444
Valproic acid treatment of episodic explosiveness related to brain injury [letter]. Geracioti Jr, Sept 416–417

Agitation
Intravenous thiothixene in the agitated patient [letter]. Merkl, Oct 456–457
Pharmacologic approach to management of agitation associated with dementia. Kunik, Feb suppl 13–17

Agranulocytosis
Agranulocytosis: incidence and risk factors. Alvir, Sept suppl B 137–138
G-CSF and the management of clozapine-induced agranulocytosis. Gerson, Sept suppl B 139–142
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. Corzo, Sept suppl B 149–152
Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. Gullion, Sept 401–405

Akathisia
Akathisia and pseudoakathisia: clinical observations and accelerometric recordings. Rapoport, Nov 473–477
Prevalence of akathisia in patients receiving stable doses of clozapine. Chengappa, Apr 142–145

Alcohol and Alcoholism
Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Osher, Mar 109–113

Alprazolam
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Amsterdam, Sept 394–400

Alzheimer's Disease
Behavioral effects of trazodone in Alzheimer's disease. Lebert, Dec 536–538
Diagnosis of Alzheimer's disease: a question of image? Jobst, Nov suppl 22–31
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. Geldmacher, Apr 161

Anorexia Nervosa
Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa [letter]. Vaz, Mar 118–119

Anticholinergic Agents
Anticholinergics to treat clozapine withdrawal [letter]. de Leon, Mar 119–120

Antidepressant Drugs see also Antidepressants, Tricyclics; Monamine Oxidase Inhibitors
Antidepressant-associated seizures [letter]. Popli, June 267
Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. Roose, Sept suppl A 83–89
Antidepressant drug selection: criteria and options. Preskorn, Sept suppl A 6–24
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. Tiffon, Feb 66–69
Depression in the medically ill: choosing an antidepressant. Cunningham, Sept suppl A 90–97
Efficacy of newer antidepressants [letter]. Buller; Workman reply, Nov 499–500
Evolutionary trends in the pharmacotherapeutic management of depression. Nemeroff, Dec suppl 3–15
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Introduction: update on antidepressant therapy. Preskorn, Sept suppl A 3–5
Natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. Keller, Sept suppl A 25–33
Pharmacogenetics and drug metabolism of newer antidepressant agents. DeVane, Dec suppl 38–45
Pharmacology of antidepressants at the synapse: focus on newer compounds. Richelson, Sept suppl A 34–41
Therapeutic considerations in treating depression in the elderly. Dunner, Dec suppl 48–58

Antidepressants, Tricyclic
Initiation of tricyclic treatment at full dose [letter]. Nelson; Warner reply, June 266–267
Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? Nierenberg, Sept suppl A 55–61
Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. McGrath, Aug 336–339

Antidiuretic Hormone
Sertraline as the cause of inappropriate antidiuretic hormone secretion [letter]. Llorente, Dec 543–544

Anxiety
Anxiety and growth disturbance: is there a connection? a review of biological studies in social phobia. Uhde, June suppl 17–27
Assessment and treatment of refractory anxiety. Hollander, Feb suppl 27–31
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Introduction. When patients don't respond: clinical strategies for managing refractory anxiety and depression. Nemiah, Feb suppl 18–19
Management of anxiety and depression syndromes in the elderly. Weiss, Feb suppl 5–12

Attention-Deficit Hyperactivity Disorder
Conceptualizing ADHD [letter]. Bellak; Pine reply, July 312–313

Back Pain
Bupropion in chronic low back pain [letter]. Davidson, Aug 362

Behavior
Behavior therapy for obsessive compulsive disorder. Greist, Oct suppl 60–68
Behavioral effects of trazodone in Alzheimer's disease. Lebert, Dec 536–538
Clozapine promotes approach-oriented behavior in male mice. Dixon, Sept suppl B 4–7

Journal of Clinical Psychiatry

Subject Index to Volume 55: January 1994 Through December 1994

Academic Highlights
Beyond efficacy: setting standards in the treatment of depression. June 270–277
Buspirone: seven-year update. May 222–229
Depression in the elderly: clinical considerations and therapeutic approaches. Apr 166–173
Focus on SSRIs: broadening the spectrum of clinical use. Oct 459–466
International advances in the treatment of social phobia. Mar 123–129
Practical approaches to the treatment of social phobia. Aug 367–374
Social phobia: outlook for the '90s. Nov 503–510

Adolescents
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97

Affective Disorders
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. Banov, July 295–300
Concurrent use of clozapine and valproate in affective and psychotic disorders. Kando, June 255–257

Aggression
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Open trial of sertraline in personality disordered patients with impulsive aggression. Kavoussi, Apr 137–141
Use of clozapine in a mentally retarded and aggressive population. Cohen, Oct 440–444
Valproic acid treatment of episodic explosiveness related to brain injury [letter]. Geracioti Jr, Sept 416–417

Agitation
Intravenous thiothixene in the agitated patient [letter]. Merkl, Oct 456–457
Pharmacologic approach to management of agitation associated with dementia. Kunik, Feb suppl 13–17

Agranulocytosis
Agranulocytosis: incidence and risk factors. Alvir, Sept suppl B 137–138
G-CSF and the management of clozapine-induced agranulocytosis. Gerson, Sept suppl B 139–142
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. Corzo, Sept suppl B 149–152
Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. Gullion, Sept 401–405

Akathisia
Akathisia and pseudoakathisia: clinical observations and accelerometric recordings. Rapoport, Nov 473–477
Prevalence of akathisia in patients receiving stable doses of clozapine. Chengappa, Apr 142–145

Alcohol and Alcoholism
Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Osher, Mar 109–113

Alprazolam
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Amsterdam, Sept 394–400

Alzheimer's Disease
Behavioral effects of trazodone in Alzheimer's disease. Lebert, Dec 536–538
Diagnosis of Alzheimer's disease: a question of image? Jobst, Nov suppl 22–31
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. Geldmacher, Apr 161

Anorexia Nervosa
Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa [letter]. Vaz, Mar 118–119

Anticholinergic Agents
Anticholinergics to treat clozapine withdrawal [letter]. de Leon, Mar 119–120

Antidepressant Drugs see also Antidepressants, Tricyclics; Monamine Oxidase Inhibitors
Antidepressant-associated seizures [letter]. Popli, June 267
Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. Roose, Sept suppl A 83–89
Antidepressant drug selection: criteria and options. Preskorn, Sept suppl A 6–24
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. Tiffon, Feb 66–69
Depression in the medically ill: choosing an antidepressant. Cunningham, Sept suppl A 90–97
Efficacy of newer antidepressants [letter]. Buller; Workman reply, Nov 499–500
Evolutionary trends in the pharmacotherapeutic management of depression. Nemeroff, Dec suppl 3–15
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Introduction: update on antidepressant therapy. Preskorn, Sept suppl A 3–5
Natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. Keller, Sept suppl A 25–33
Pharmacogenetics and drug metabolism of newer antidepressant agents. DeVane, Dec suppl 38–45
Pharmacology of antidepressants at the synapse: focus on newer compounds. Richelson, Sept suppl A 34–41
Therapeutic considerations in treating depression in the elderly. Dunner, Dec suppl 48–58

Antidepressants, Tricyclic
Initiation of tricyclic treatment at full dose [letter]. Nelson; Warner reply, June 266–267
Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? Nierenberg, Sept suppl A 55–61
Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. McGrath, Aug 336–339

Antidiuretic Hormone
Sertraline as the cause of inappropriate antidiuretic hormone secretion [letter]. Llorente, Dec 543–544

Anxiety
Anxiety and growth disturbance: is there a connection? a review of biological studies in social phobia. Uhde, June suppl 17–27
Assessment and treatment of refractory anxiety. Hollander, Feb suppl 27–31
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Introduction. When patients don't respond: clinical strategies for managing refractory anxiety and depression. Nemiah, Feb suppl 18–19
Management of anxiety and depression syndromes in the elderly. Weiss, Feb suppl 5–12

Attention-Deficit Hyperactivity Disorder
Conceptualizing ADHD [letter]. Bellak; Pine reply, July 312–313

Back Pain
Bupropion in chronic low back pain [letter]. Davidson, Aug 362

Behavior
Behavior therapy for obsessive compulsive disorder. Greist, Oct suppl 60–68
Behavioral effects of trazodone in Alzheimer's disease. Lebert, Dec 536–538
Clozapine promotes approach-oriented behavior in male mice. Dixon, Sept suppl B 4–7

Behavior Therapy
Cognitive behavior therapy for treatment-refractory panic disorder. Pollack, May 200–205
Obsessive compulsive patients with comorbid personality disorder: associated problems and response to a comprehensive behavior therapy. AuBuchon, Oct 448–453
Treatment of social phobia in cognitive-behavioral groups. Heimberg, June suppl 38–46
Benzodiazepines
Treatment of social phobia with benzodiazepines. Davidson, June suppl 28–32
Benztropine
Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Roth, Nov 492–495
Bereavement
Spectrum of depressive phenomena after spousal bereavement. Zisook, Apr suppl 29–36
Bipolar Disorder
Is there a role for neuroleptics in bipolar disorder? Hendrick, Dec 533–535
Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. Risinger, May 215
Blindness
Familial psychogenic blindness and headache: a case study. Ziegler, Mar 114–117
Blood Disorders
Clozapine-induced transient white blood count disorders. Hummer, Oct 429–432
Blood Levels
Lack of effect of fluoxetine on plasma clozapine concentrations [letter]. Eggert, Oct 454–455
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. Miller, Sept suppl B 117–121
Body Dysmorphic Disorder
Trichotillomania and body dysmorphic disorder [letter]. Tanquary; Winchel reply, Jan 35–36
Books Reviewed
Archer RP: *MMPI-A: Assessing Adolescent Psychopathology.* Battle, July 318
Barker P: *Basic Family Therapy.* Scott, Mar 122
Bornstein RF: *The Dependent Personality.* Allen, Dec 547
Cameron NMdeS: *The New Medicine: Life and Death After Hippocrates.* Hart, Oct 458
Coffey CE (ed): *The Clinical Science of Electroconvulsive Therapy.* Walker, Sept 419
Dalton R, Forman MA: *Psychiatric Hospitalization of School-Age Children.* Kontras, June 269
Foy DW (ed): *Treating PTSD: Cognitive-Behavioral Strategies.* Becker, Feb 81
GAP report No. 134: *Beyond Symptom Suppression: Improving Long-Term Outcomes in Schizophrenia.* Roederer, May 220-221
Gibson HB, Heap M: *Hypnosis in Therapy.* Battle, Aug 365
Goodman M, Brown J, Dietz P: *Managing Managed Care: A Mental Health Practitioner's Survival Guide.* Larocca, Sept 419
Greenberg DA, Aminoff MJ, Simon RP: *Clinical Neurology.* Bertorini, Feb 81
Greenspan SI: *Infancy and Early Childhood: The Practice of Clinical Assessment and Intervention With Emotional and Developmental Challenges.* Eppright, Jan 40
Greist JH, Jefferson JW: *Depression and Its Treatment, 2nd ed.* Haykal, Feb 80
Halmi KA (ed): *Psychobiology and Treatment of Anorexia Nervosa and Bulimia Nervosa.* Rosenthal, Sept 418–419
Hanu Y: *Far Journey: A Psychiatrist's Chronicle.* Frenkel, Oct 458
Jack R: *Women and Attempted Suicide.* Scott, May 219–220
Jacobs D (ed): *Suicide and Clinical Practice.* Alarcon, Apr 165
Janicak PG, Davis JM, Preskorn SH, Ayd FJ (eds): *Principles and Practice of Psychopharmacotherapy.* Brown, Nov 502
Kane JM, Lieberman JA (eds): *Adverse Effects of Psychotropic Drugs.* Vadnal and Parthasarathy, July 318
Katz SE, Nardacci D, Sabatini A (eds): *Intensive Treatment of the Homeless Mentally Ill.* Scott, Mar 121
Klein DF, Wender PH: *Understanding Depression: A Complete Guide to Its Diagnosis and Treatment.* Newhouse, Aug 366
Linehan MM: *Cognitive-Behavioral Treatment of Borderline Personality Disorder.* Allen, Nov 501–502
Musa MN (ed): *Pharmacokinetics and Therapeutic Monitoring of Psychiatric Drugs.* Brown, Dec 547
Nakazawa T: *Biological Basis of Schizophrenic Disorders.* Gold Jr, Aug 365–366
O'Brien ME: *Living With HIV: Experiment in Courage.* Lee, Feb 80
Paris J (ed): *Borderline Personality Disorder: Etiology and Treatment.* Allen, Sept 418
Reynolds WM (ed): *Internalizing Disorders in Children and Adolescents.* Breedlove, July 318
Sadavoy J, Lazarus LW, Jarvik LF (eds): *Comprehensive Review of Geriatric Psychiatry.* Lawrence, June 268
Sandler J (ed): *The Harvard Lectures—Anna Freud.* Seelig, July 317
Sher KJ: *Children of Alcoholics: A Critical Appraisal of Theory and Research.* VanValkenburg, May 220
Silver D, Rosenbluth M (eds): *Handbook of Borderline Disorders.* Allen, June 268–269
Sugarman A, Nemiroff RA, Greenson D (eds): *The Technic and Practice of Psychoanalysis, Volume 2.* Stone, Feb 80–81
USDHHS: *Outcasts on Main Street: Report of the Federal Task Force on Homelessness and Severe Mental Illness.* Gold, July 317
Yeomans FE, Selzer MA, Clarkin JF: *Treating the Borderline Patient: A Contract-Based Approach.* Allen, Nov 501
Borderline Personality Disorder
Prognostic implications of stable versus transient "borderline features" in bulimic patients. Steiger, May 206–214
Brain
Brain region effects of clozapine on amino acid and monoamine transmission. Yamamoto, Sept suppl B 8–14
Cerebral morphometry and clozapine treatment in schizophrenia. Bilder, Sept suppl B 53–56
Clozapine effects on glucose metabolic rate in striatum and frontal cortex. Potkin, Sept suppl B 63–66
Limbic-prefrontal connectivity and clozapine. Knable, Sept suppl B 70–73
Brain Imaging
Clinical correlates of PET- and SPECT-identified defects in dementia. Mayberg, Nov suppl 12–21
Diagnosis of Alzheimer's disease: a question of image? Jobst, Nov suppl 22–31
Functional imaging in dementia: an overview. Jagust, Nov suppl 5–11
Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. Kerwin, Sept suppl B 57–62
Geriatric depression: brain imaging correlates and pharmacologic considerations. Drevets, Sept suppl A 71–82
Introduction: neuroimaging assessment of cognitive disorders. Andreasen, Nov suppl 3–4
Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorder. Baxter Jr, Oct suppl 54–59
Brain Injuries
Valproic acid treatment of episodic explosiveness related to brain injury [letter]. Geracioti Jr, Sept 416–417
Bromocriptine
Treatment of refractory OCD with the dopamine agonist bromocriptine [letter]. Ceccherini-Nelli, Sept 415–416
Bulimia Nervosa
Childhood abuse, family environment, and outcome in bulimia nervosa. Fallon, Oct 424–428
Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa [letter]. Vaz, Mar 118–119
One-year follow-up of psychosocial and pharmacologic treatment for bulimia nervosa. Agras, May 179–183
Prognostic implications of stable versus transient "borderline features" in bulimic patients. Steiger, May 206–214
Bupropion
Bupropion in chronic low back pain [letter]. Davidson, Aug 362
Double-blind trial of bupropion versus desipramine for bipolar depression. Sachs, Sept 391–393
Buspirone
Biochemical and clinical effects of buspirone augmentation [letter]. Howland, June 264
Carbamazepine
Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. Stuppaeck, Apr 146–150
Efficacy of carbamazepine compared with other agents: a clinical practice survey. Denicoff, Feb 70–76
Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. Brewerton, June 249–251
Cardiac Function
Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. Roose, Sept suppl A 83–89
Asystole in ECT [letter]. Rasmussen; Liebowitz reply, July 313–314
Catatonia
Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. Gaind, Jan 20–23
Child Abuse
Childhood abuse, family environment, and outcome in bulimia nervosa. Fallon, Oct 424–428
Children
Childhood movement disorders and obsessive compulsive disorder. Swedo, Mar suppl 32–37

Cholesterol
Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. Modai, June 252–254
Clomipramine
Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind parallel group comparison. Freeman, July 301–305
Clonidine
Clonidine patch: reservoir for abuse [letter]. Fetrow, June 266
Clozapine
^{51}CR release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. Pisciotta, Sept suppl B 143–148
Agranulocytosis: incidence and risk factors. Alvir, Sept suppl B 137–138
Anticholinergics to treat clozapine withdrawal [letter]. de Leon, Mar 119–120
Apparent neurotoxicity associated with clozapine [letter]. Viner, Jan 38–39
Brain region effects of clozapine on amino acid and monoamine transmission. Yamamoto, Sept suppl B 8–14
Cerebral morphometry and clozapine treatment in schizophrenia. Bilder, Sept suppl B 53–56
Clinical usefulness of clozapine [letter]. Reid; Wilson reply, Dec 546
Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. Breier, Sept suppl B 122–125
Clozapine and weight gain. Umbricht, Sept suppl B 157–160
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. Fleischhacker, Sept suppl B 78–81
Clozapine effects on glucose metabolic rate in striatum and frontal cortex. Potkin, Sept suppl B 63–66
Clozapine following ECT: a two-step treatment. Green, Sept 388–390
Clozapine-induced orthostatic hypotension treated with fludrocortisone [letter]. Testani Jr, Nov 497–498
Clozapine-induced transient white blood count disorders. Hummer, Oct 429–432
Clozapine in tardive dyskinesia: observations from human and animal model studies. Tamminga, Sept suppl B 102–106
Clozapine in treatment-refractory mood disorders. Kimmel, Sept suppl B 91–93
Clozapine, negative symptoms, and extrapyramidal side effects. Kane, Sept suppl B 74–77
Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system. Gardner, Sept suppl B 15–22
Clozapine promotes approach-oriented behavior in male mice. Dixon, Sept suppl B 4–7
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. Banov, July 295–300
Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. Peacock, Feb 44–49
Clozapine treatment of psychosis in patients with Parkinson's disease. Friedman; Wolk reply, Feb 79
Concurrent use of clozapine and valproate in affective and psychotic disorders. Kando, June 255–257
D_1-, D_2-, and 5-HT_2-receptor occupancy in clozapine-treated patients. Farde, Sept suppl B 67–69
Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. Leadbetter, Sept suppl B 110–113
Effects of clozapine on cognitive function in schizophrenia. Lee, Sept suppl B 82–87
Effects of clozapine on neurocognition: an overview. Goldberg, Sept suppl B 88–90
Effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Kinkead, Sept suppl B 30–32
Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. Olney, Sept suppl B 43–46
Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. Kerwin, Sept suppl B 57–62
G-CSF and the management of clozapine-induced agranulocytosis. Gerson, Sept suppl B 139–142
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. Corzo, Sept suppl B 149–152
Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. Deutch, Sept suppl B 37–42
Lack of effect of fluoxetine on plasma clozapine concentrations [letter]. Eggert, Oct 454–455
Limbic-prefrontal connectivity and clozapine. Knable, Sept suppl B 70–73
More on obsessive-compulsive symptoms and clozapine [letter]. LaPorta; Baker reply, July 312
Motor and mental side effects of clozapine. Gerlach, Sept suppl B 107–109
Overview of the mechanism of action of clozapine. Meltzer, Sept suppl B 47–52
Pharmacoeconomics of clozapine: a review. Meltzer, Sept suppl B 161–165
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. Miller, Sept suppl B 117–121
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Potkin, Sept suppl B 133–136
Predictors of clozapine response in schizophrenia. Pickar, Sept suppl B 129–132
Predictors of response to clozapine. Lieberman, Sept suppl B 126–128
Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. Moghaddam, Sept suppl B 27–29
Prevalence of akathisia in patients receiving stable doses of clozapine. Chengappa, Apr 142–145
Role of 5-HT_3-like receptors in the action of clozapine. Wang, Sept suppl B 23–26
Seizures and clozapine dosing schedule [letter]. Chengappa, Oct 456
Seizures associated with clozapine treatment in a state hospital. Wilson, May 184–188
Seizures during clozapine therapy. Devinsky, Sept suppl B 153–156
Substance abuse and clozapine treatment. Buckley, Sept suppl B 114–116
Successful clozapine rechallenge following prior intolerance to clozapine [letter]. Cohen, Nov 498–499
Tardive oculogyric crises with clozapine [letter]. Dave, June 264–265
Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. Gullion, Sept 401–405
Use of clozapine in neurologic disorders. Safferman, Sept suppl B 98–101
Use of clozapine in a mentally retarded and aggressive population. Cohen, Oct 440–444
Use of desmopressin to treat clozapine-induced nocturnal enuresis [letter]. Steingard, July 315–316
Cognitive Disorders
Introduction: neuroimaging assessment of cognitive disorders. Andreasen, Nov suppl 3–4
Cognitive Function
Effects of clozapine on cognitive function in schizophrenia. Lee, Sept suppl B 82–87
Effects of clozapine on neurocognition: an overview. Goldberg, Sept suppl B 88–90
Cognitive Therapy
Cognitive behavior therapy for treatment-refractory panic disorder. Pollack, May 200–205
Treatment of social phobia in cognitive-behavioral groups. Heimberg, June suppl 38–46
Comorbidity
Compulsive buying: descriptive characteristics and psychiatric comorbidity. Christenson, Jan 5–11
Obsessive compulsive disorder: comorbid conditions. Pigott, Oct suppl 15–32
Overview. OCD: comorbidity and management dilemmas. Jenike, Mar suppl 3–4
Preliminary observations of DSM-III-R Axis I comorbidity in men with paraphilias and paraphilia-related disorders. Kafka, Nov 481–487
Compulsive Buying
Compulsive buying: a report of 20 cases. McElroy, June 242–248
Compulsive buying: descriptive characteristics and psychiatric comorbidity. Christenson, Jan 5–11
Do compulsive buyers and kleptomaniacs share identical characteristics? [letter] Fishbain; Christenson reply, Dec 545–546
Continuation Treatment
Guidelines for the long-term treatment of depression. Hirschfeld, Dec suppl 61–69
Cyproheptadine
Adverse interaction of cyproheptadine with serotonergic antidepressants [letter]. Katz, July 314–315
Cytotoxicity
^{51}CR release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. Pisciotta, Sept suppl B 143–148
Delirium
Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Roth, Nov 492–495
Delusions
Erotomanic delusions and electroconvulsive therapy: a case series. Remington, July 306–308
Demeclocycline
Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. Brewerton, June 249–251
Dementia
Clinical correlates of PET- and SPECT-identified defects in dementia. Mayberg, Nov suppl 12–21
Familial presenile dementia with motor neuron disease [letter]. Kellner, Nov 496–497
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. Geldmacher, Apr 161

Functional imaging in dementia: an overview. Jagust, Nov suppl 5–11
Pharmacologic approach to management of agitation associated with dementia. Kunik, Feb suppl 13–17
Denmark
Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. Peacock, Feb 44–49
Depression
Assessment and treatment of refractory depression. Phillips, Feb suppl 20–26
Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. Dubovsky, Feb suppl 34–44
Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. Stuppaeck, Apr 146–150
Characteristics of desipramine-refractory depression. Nelson, Jan 12–19
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer, Mar 104–108
Depression as a lethal disease: prevention strategies. Coppen, Apr suppl 37–45
Depression in the medically ill: choosing an antidepressant. Cunningham, Sept suppl A 90–97
Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Ferguson, June 258–263
Double-blind comparison of nefazodone, imipramine, and placebo in major depression. Fontaine, June 234–241
Double-blind trial of bupropion versus desipramine for bipolar depression. Sachs, Sept 391–393
Dysthymic and cyclothymic depressions: therapeutic considerations. Akiskal, Apr suppl 46–52
Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Rabkin, Mar 92–97
Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. Rabkin, Oct 433–439
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Amsterdam, Sept 394–400
Evolutionary trends in the pharmacotherapeutic management of depression. Nemeroff, Dec suppl 3–15
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Geriatric depression: brain imaging correlates and pharmacologic considerations. Drevets, Sept suppl A 71–82
Guidelines for the long-term treatment of depression. Hirschfeld, Dec suppl 61–69
Introduction. New agents for the treatment of depression. Greden, Feb suppl 32–33
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Introduction. When patients don't respond: clinical strategies for managing refractory anxiety and depression. Nemiah, Feb suppl 18–19
Management of anxiety and depression syndromes in the elderly. Weiss, Feb suppl 5–12
Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L. Jefferson, Aug 340–343
Measuring response in treatment of depression [letter]. Blum; Preskorn reply, Feb 77
Natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. Keller, Sept suppl A 25–33
Norplant-associated major depression and panic disorder. Wagner, Nov 478–480
Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. Burke, Sept suppl A 42–54
Potential benefits of serotonin receptor-specific agents. Sussman, Feb suppl 45–51
Psychostimulant suppository treatment for depression in the gravely ill [letter]. Holmes, June 265–266
Recognition and treatment of depression in a primary care setting. Montano, Dec suppl 18–34
Recurrent brief depression: the Zurich study. Angst, Apr suppl 3–9
Role of venlafaxine in rational antidepressant therapy. Feighner, Sept suppl A 62–70
Spectrum of depressive phenomena after spousal bereavement. Zisook, Apr suppl 29–36
Subsyndromal symptomatic depression: a new mood disorder? Judd, Apr suppl 18–28
Suicide in major depression in different treatment settings. Isometsä, Dec 523–527
Therapeutic considerations in treating depression in the elderly. Dunner, Dec suppl 48–58
Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? Nierenberg, Sept suppl A 55–61
Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. McGrath, Aug 336–339
Depressive Personality Disorder
Depressive personality disorder: clinical implications. Hirschfeld, Apr suppl 10–17
Desipramine
Characteristics of desipramine-refractory depression. Nelson, Jan 12–19
Double-blind trial of bupropion versus desipramine for bipolar depression. Sachs, Sept 391–393
Desmopressin
Use of desmopressin to treat clozapine-induced nocturnal enuresis [letter]. Steingard, July 315–316
Diagnosis
Management of anxiety and depression syndromes in the elderly. Weiss, Feb suppl 5–12
Diagnosis and Classification
Depressive personality disorder: clinical implications. Hirschfeld, Apr suppl 10-17
Do compulsive buyers and kleptomaniacs share identical characteristics? [letter] Fishbain; Christenson reply, Dec 545–546
Preliminary observations of DSM-III-R Axis I comorbidity in men with paraphilias and paraphilia-related disorders. Kafka, Nov 481–487
Subsyndromal symptomatic depression: a new mood disorder? Judd, Apr suppl 18–28
Diagnosis, Differential
Diagnostic reassessment and treatment response in schizophrenia. Honer, Dec 528–532
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Oct suppl 5–14
Misuse of the face-hand test for psychogenic neurologic deficits [letter]. Reeves, Aug 363
Divalproex Sodium
Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. Risinger, May 215
Dopamine
Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system. Gardner, Sept suppl B 15–22
D_1-,D_2-, and 5-HT_2-receptor occupancy in clozapine-treated patients. Farde, Sept suppl B 67–69
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. McDougle, Mar suppl 24–31
Fluoxetine-dopaminergic interaction data [letter]. Beasley Jr; Hamilton reply, Feb 77–79
Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. Kerwin, Sept suppl B 57–62
Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. Moghaddam, Sept suppl B 27–29
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Leysen, May suppl 5–12
Dosage
Adequate testing of lithium dose prediction [letter]. Swartz; Cummings reply, May 215–216
Enhancing compliance in schizophrenic patients by weekly dosing with levothyroxine sodium [letter]. Walch, Dec 543
Initiation of tricyclic treatment at full dose [letter]. Nelson; Warner reply, June 266–267
Seizures and clozapine dosing schedule [letter]. Chengappa, Oct 456
Dothiepin
Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Ferguson, June 258–263
Doxepin
Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Ferguson, June 258–263
Drug Administration Route
Clonidine patch: reservoir for abuse [letter]. Fetrow, June 266
Psychostimulant suppository treatment for depression in the gravely ill [letter]. Holmes, June 265–266
Intravenous thiothixene in the agitated patient [letter]. Merkl, Oct 456–457
Underutilization of depot neuroleptic therapy [letter]. Balon; Glazer reply, Jan 39
Drug Interactions
Adverse interaction of cyproheptadine with serotonergic antidepressants [letter]. Katz, July 314–315
Drug Intolerance
Successful clozapine rechallenge following prior intolerance to clozapine [letter]. Cohen, Nov 498–499
Drug Side Effects
Hair loss associated with fluoxetine use in two family members [letter]. Mareth, Apr 163
Motor and mental side effects of clozapine. Gerlach, Sept suppl B 107–109
Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. Gitlin, Sept 406–413
SSRI withdrawal buzz [letter]. Ellison, Dec 544–545
Drug Therapy, Combination
Biochemical and clinical effects of buspirone augmentation [letter]. Howland, June 264
Combined SSRI-moclobemide treatment of psychiatric illness. Joffe, Jan 24–25

Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Roth, Nov 492–495
Drug Withdrawal
SSRI withdrawal buzz [letter]. Ellison, Dec 544–545
Eating Disorders see also Anorexia Nervosa; Bulimia Nervosa
Aberrant snacking patterns and eating disorders in patients with obsessive compulsive disorder. O'Rourke, Oct 445–447
Economics
Cost of HLA typing [letter]. Grove; Landy reply, Roerig reply, Oct 455–456
Pharmacoeconomics of clozapine: a review. Meltzer, Sept suppl B 161–165
Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. Burke, Sept suppl A 42–54
Treatment of psychosis: resetting the drug cost "thermostat". Reid, Sept suppl B 166–168
Elderly
Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. Risinger, May 215
Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Tucker, Feb suppl 3–4
Management of anxiety and depression syndromes in the elderly. Weiss, Feb suppl 5–12
Therapeutic considerations in treating depression in the elderly. Dunner, Dec suppl 48–58
Electroconvulsive Therapy
Asystole in ECT [letter]. Rasmussen; Liebowitz reply, July 313–314
Clozapine following ECT: a two-step treatment. Green, Sept 388–390
Erotomanic delusions and electroconvulsive therapy: a case series. Remington, July 306–308
Maintenance electroconvulsive therapy in schizophrenia [letter]. Lohr, May 217–218
Electrolytes
Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? Goldman, Apr 151–153
Emergency Psychiatry
No harm contract in the emergency assessment of suicidal risk. Stanford, Aug 344–348
Enuresis
Use of desmopressin to treat clozapine-induced nocturnal enuresis [letter]. Steingard, July 315–316
Epidemiology
Cross national epidemiology of obsessive compulsive disorder. Weissman, Mar suppl 5–10
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Oct suppl 5–14
Erotomania
Erotomanic delusions and electroconvulsive therapy: a case series. Remington, July 306–308
Etiology
Etiology of social phobia. Rosenbaum, June suppl 10–16
Exhibitionism
Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. Zohar, Mar 86–88
Extrapyramidal Side Effects
Clozapine, negative symptoms, and extrapyramidal side effects. Kane, Sept suppl B 74–77
Extrapyramidal side effects and tolerability of risperidone: a review. Owens, May suppl 29–35
Face-Hand Test
Misuse of the face-hand test for psychogenic neurologic deficits [letter]. Reeves, Aug 363
Family
Childhood abuse, family environment, and outcome in bulimia nervosa. Fallon, Oct 424–428
Familial psychogenic blindness and headache: a case study. Ziegler, Mar 114–117
Hair loss associated with fluoxetine use in two family members [letter]. Mareth, Apr 163
Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. Gaind, Jan 20–23
Fifth Psychoactive Drug Usage Guide
Fifth Psychoactive Drug Usage Guide [letter]. Wilson; Appleton reply, Jan 34–35
Filgrastim
Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. Gullion, Sept 401–405
Fludrocortisone
Clozapine-induced orthostatic hypotension treated with fludrocortisone [letter]. Testani Jr, Nov 497–498
Fluoxetine
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. Tiffon, Feb 66–69
Case report of paradoxical sedation with fluoxetine therapy [letter]. Gupta, Mar 118
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Tollefson, Oct suppl 69–78
Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Rabkin, Mar 92–97
Fluoxetine-dopaminergic interaction data [letter]. Beasley Jr; Hamilton reply, Feb 77–79
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. Geldmacher, Apr 161
Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa [letter]. Vaz, Mar 118–119
Fluoxetine in posttraumatic stress disorder. van der Kolk, Dec 517–522
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Tollefson, Feb 50–59
Hair loss associated with fluoxetine use in two family members [letter]. Mareth, Apr 163
Lack of effect of fluoxetine on plasma clozapine concentrations [letter]. Eggert, Oct 454–455
Long-term fluoxetine treatment of late luteal phase dysphoric disorder. Pearlstein, Aug 332–335
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Amsterdam, Sept 394–400
Sexual obsessions associated with fluoxetine [letter]. Balon, Nov 496
Fluvoxamine
Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. Zohar, Mar 86–88
Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind parallel group comparison. Freeman, July 301–305
Frontal Lobe
Serotonergic agents and frontal lobe syndrome [letter]. Opler, Aug 362–363
Functional Impairment
Functional impairment in social phobia. Schneier, Aug 322–331
Genetics
Familial presenile dementia with motor neuron disease [letter]. Kellner, Nov 496–497
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. Corzo, Sept suppl B 149–152
Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. Deutch, Sept suppl B 37–42
Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. Fibiger, Sept suppl B 33–36
Pharmacogenetics and drug metabolism of newer antidepressant agents. DeVane, Dec suppl 38–45
Geriatric Psychiatry
Geriatric depression: brain imaging correlates and pharmacologic considerations. Drevets, Sept suppl A 71–82
Glucose
Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorder. Baxter Jr, Oct suppl 54–59
Granulocyte Colony-Stimulating Factor
G-CSF and the management of clozapine-induced agranulocytosis. Gerson, Sept suppl B 139–142
Growth
Anxiety and growth disturbance: is there a connection? a review of biological studies in social phobia. Uhde, June suppl 17–27
Gustatory Function
Zinc salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. Stoll, July 309–311
Hair
Hair loss associated with fluoxetine use in two family members [letter]. Mareth, Apr 163
Hair pulling see Trichotillomania
Hallucination
Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. Sokolski, Sept 380–387
Haloperidol
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97
Harakiri
Harakiri: a clinical study of deliberate self-stabbing. Patel, Mar 98–103
Headache
Familial psychogenic blindness and headache: a case study. Ziegler, Mar 114–117
HLA Typing
Cost of HLA typing [letter]. Grove; Landy reply, Roerig reply, Oct 455–456
Human Immunodeficiency Virus
Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Rabkin, Mar 92–97
Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. Rabkin, Oct 433–439
Hyponatremia
Commentary: severe hyponatremia in the polydipsia-hyponatremia syndrome. Vieweg, Aug 355–361
Commentary: treatment strategies in the polydipsia-hyponatremia syndrome. Vieweg, Apr 154–160
Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. Leadbetter, Sept suppl B 110–113

Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? Goldman, Apr 151–153
High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. Tanneau, Aug 349–354
Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. Brewerton, June 249–251
Hypotension, Orthostatic
Clozapine-induced orthostatic hypotension treated with fludrocortisone [letter]. Testani Jr, Nov 497–498
Imipramine
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer, Mar 104–108
Double-blind comparison of nefazodone, imipramine, and placebo in major depression. Fontaine, June 234–241
Immune System
Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Rabkin, Mar 92–97
In Memoriam
John Romano, M.D., 1908–1994. Racy, Sept 379
Inpatients
Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. Modai, June 252–254
Insomnia
Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. Mendels, Feb 60–65
Multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. Scharf, May 192–199
Trends in the pharmacologic treatment of insomnia [letter]. Pearce; Walsh reply, Apr 163–164
Japan
Is psychopathology in Japan a "black hole"? [letter] Okada, Apr 164
Jealousy
Serotonin reuptake blockers for the treatment of obsessional jealousy. Stein, Jan 30–33
Jitteriness
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Amsterdam, Sept 394–400
Journal of Clinical Psychiatry
JCP at mid-decade [editorial]. Gelenberg, Dec 515–516
Kleptomania
Do compulsive buyers and kleptomaniacs share identical characteristics? [letter] Fishbain; Christenson reply, Dec 545–546
Late Luteal Phase Dysphoric Disorder
Long-term fluoxetine treatment of late luteal phase dysphoric disorder. Pearlstein, Aug 332–335
Levothyroxine Sodium
Enhancing compliance in schizophrenic patients by weekly dosing with levothyroxine sodium [letter]. Walch, Dec 543
Light Therapy
Mania precipitated by light therapy for patients with SAD [letter]. Chan, Oct 454
Side effects induced by bright light treatment for seasonal affective disorder. Labbate, May 189–191
Lithium
Adequate testing of lithium dose prediction [letter]. Swartz; Cummings reply, May 215–216
Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L. Jefferson, Aug 340–343
Potassium supplementation during lithium therapy [letter]. Klemfuss; Jefferson reply, Jan 36
Lorazepam
Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. Gaind, Jan 20–23
Maintenance Treatment
Guidelines for the long-term treatment of depression. Hirschfeld, Dec suppl 61–69
Mania
Mania precipitated by light therapy for patients with SAD [letter]. Chan, Oct 454
Rapid resolution of first episodes of mania: sleep related? Nowlin-Finch, Jan 26–29
Maupassant, Guy de
Guy de Maupassant's "The Horla" and sleep paralysis [letter]. Schneck, Dec 544
Medical Illness
Depression in the medically ill: choosing an antidepressant. Cunningham, Sept suppl A 90–97
Mental Retardation
Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. Gaind, Jan 20–23
Use of clozapine in a mentally retarded and aggressive population. Cohen, Oct 440–444
Moclobemide
Combined SSRI-moclobemide treatment of psychiatric illness. Joffe, Jan 24–25
Monoamine Oxidase Inhibitors
Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. McGrath, Aug 336–339
Mood
Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Rabkin, Mar 92–97
Mood Disorder
Clozapine in treatment-refractory mood disorders. Kimmel, Sept suppl B 91–93
Motor Neuron Disease
Familial presenile dementia with motor neuron disease [letter]. Kellner, Nov 496–497
Movement Disorders
Childhood movement disorders and obsessive compulsive disorder. Swedo, Mar suppl 32–37
Multiple Chemical Sensitivities
Outpatient treatment for "multiple chemical sensitivities" [letter]. Boxer, July 316
Nefazodone
Double-blind comparison of nefazodone, imipramine, and placebo in major depression. Fontaine, June 234–241
Negative Symptoms
Clozapine, negative symptoms, and extrapyramidal side effects. Kane, Sept suppl B 74–77
Negative symptoms in schizophrenia: assessment of the effect of risperidone. Schooler, May suppl 22–28
Neuroleptic Drugs
Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Roth, Nov 492–495
Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. Leadbetter, Sept suppl B 110–113
Effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Kinkead, Sept suppl 30–32
Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. Olney, Sept suppl B 43–46
Is there a role for neuroleptics in bipolar disorder? Hendrick, Dec 533–535
Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. Fibiger, Sept suppl B 33–36
Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon. Bermanzohn, Nov 488–491
Underutilization of depot neuroleptic therapy [letter]. Balon; Glazer reply, Jan 39
Neurologic Disorders
Use of clozapine in neurologic disorders. Safferman, Sept suppl B 98–101
Neurologic Manifestations
High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. Tanneau, Aug 349–354
Misuse of the face-hand test for psychogenic neurologic deficits [letter]. Reeves, Aug 363
Neurotensin
Effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Kinkead, Sept suppl B 30–32
Neurotoxicity
Apparent neurotoxicity associated with clozapine [letter]. Viner, Jan 38–39
Neurotransmission
Brain region effects of clozapine on amino acid and monoamine transmission. Yamamoto, Sept suppl B 8–14
Pharmacology of antidepressants at the synapse: focus on newer compounds. Richelson, Sept suppl A 34–41
No Harm Contract
No harm contract in the emergency assessment of suicidal risk. Stanford, Aug 344–348
Norepinephrine
Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. Breier, Sept suppl B 122–125
Norplant
Norplant-associated major depression and panic disorder. Wagner, Nov 478–480
Obsessive Compulsive Disorder
Aberrant snacking patterns and eating disorders in patients with obsessive compulsive disorder. O'Rourke, Oct 445–447
Behavior therapy for obsessive compulsive disorder. Greist, Oct suppl 60–68
Childhood movement disorders and obsessive compulsive disorder. Swedo, Mar suppl 32–37
Commentary: obsessive compulsive spectrum disorders. Rasmussen, Mar 89–91
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Tollefson, Oct suppl 69–78
Cross national epidemiology of obsessive compulsive disorder. Weissman, Mar suppl 5–10
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. McDougle, Mar suppl 24–31
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Oct suppl 5–14
Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. Baer, Mar suppl 18–23

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind parallel group comparison. Freeman, July 301–305
Introduction: new developments in the treatment of obsessive compulsive disorders. Jenike, Oct suppl 3–4
Management of treatment-refractory obsessive compulsive disorder patients. Dominguez, Oct suppl 86–92
Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. Jenike, Mar suppl 11–17
More on obsessive-compulsive symptoms and clozapine [letter]. LaPorta; Baker reply, July 312
Obsessive compulsive disorder: comorbid conditions. Pigott, Oct suppl 15–32
Obsessive compulsive disorder in primary care. Shahady, Oct suppl 79–85
Obsessive compulsive patients with comorbid personality disorder: associated problems and response to a comprehensive behavior therapy. AuBuchon, Oct 448–453
Obsessive compulsive spectrum disorder. McElroy, Oct suppl 33–53
Overview. OCD: comorbidity and management dilemmas. Jenike, Mar suppl 3–4
Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorder. Baxter Jr, Oct suppl 54–59
Treatment of refractory OCD with the dopamine agonist bromocriptine [letter]. Ceccherini-Nelli, Sept 415–416
Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. Deltito, Nov 500

Olfactory Function
Zinc salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. Stoll, July 309–311

Outcome
Characteristics of desipramine-refractory depression. Nelson, Jan 12–19
Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Osher, Mar 109–113

Outpatients
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer, Mar 104–108
Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Osher, Mar 109–113
Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. Mendels, Feb 60–65

Panic Disorder
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. Tiffon, Feb 66–69
Cognitive behavior therapy for treatment-refractory panic disorder. Pollack, May 200–205
Commentary: pregnancy and panic disorder. Klein, July 293–294
Impact of pregnancy on panic disorder: a case series. Cohen, July 284–288
Norplant-associated major depression and panic disorder. Wagner, Nov 478–480
Panic disorder in pregnancy. Northcott, Dec 539–542
Panic disorder: treatment with valproate. Woodman, Apr 134–136
Postpartum course in women with preexisting panic disorder. Cohen, July 289–292

Paraphilias
Preliminary observations of DSM-III-R Axis I comorbidity in men with paraphilias and paraphilia-related disorders. Kafka, Nov 481–487

Paresis
Misuse of the face-hand test for psychogenic neurologic deficits [letter]. Reeves, Aug 363

Parkinson's Disease
Clozapine treatment of psychosis in patients with Parkinson's disease [letter]. Friedman; Wolk reply, Feb 79

Paroxetine
Paroxetine efficacy in social phobia [letter]. Ringold, Aug 363–364

Personality Disorder
Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. Baer, Mar suppl 18–23
Obsessive compulsive patients with comorbid personality disorder: associated problems and response to a comprehensive behavior therapy. AuBuchon, Oct 448–453
Open trial of sertraline in personality disordered patients with impulsive aggression. Kavoussi, Apr 137–141

PET
Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorder. Baxter Jr, Oct suppl 54–59

Pharmacokinetics
Pharmacokinetics of risperidone in humans: a summary. Heykants, Apr suppl 13–17

Phenelzine
Phenelzine and sexuality [letter]. Warneke; Golwyn reply, May 216–217

Polydipsia
Commentary: severe hyponatremia in the polydipsia-hyponatremia syndrome. Vieweg, Aug 355–361
Commentary: treatment strategies in the polydipsia-hyponatremia syndrome. Vieweg, Apr 154–160
Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. Leadbetter, Sept suppl B 110–113
High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. Tanneau, Aug 349–354

Positive Symptoms
Efficacy of risperidone on positive features of schizophrenia. McEvoy, May suppl 18–21

Postpartum Period
Postpartum course in women with preexisting panic disorder. Cohen, July 289–292

Posttraumatic Stress Disorder
Fluoxetine in posttraumatic stress disorder. van der Kolk, Dec 517–522

Potassium
Potassium supplementation during lithium therapy [letter]. Klemfuss; Jefferson reply, Jan 36

Prediction
Characteristics of desipramine-refractory depression. Nelson, Jan 12–19

Pregnancy
Commentary: pregnancy and panic disorder. Klein, July 293–294
Impact of pregnancy on panic disorder: a case series. Cohen, July 284–288
Panic disorder in pregnancy. Northcott, Dec 539–542

Prescribing Practices
Nonphysician prescribers [letter]. Jann, Sept 414

Primary Care
Obsessive compulsive disorder in primary care. Shahady, Oct suppl 79–85
Recognition and treatment of depression in a primary care setting. Montano, Dec suppl 18–34

Professional Practice
Efficacy of carbamazepine compared with other agents: a clinical practice survey. Denicoff, Feb 70–76
Nonphysician prescribers [letter]. Jann, Sept 414

Prognosis
Prognostic implications of stable versus transient "borderline features" in bulimic patients. Steiger, May 206–214

Pseudoakathisia
Akathisia and pseudoakathisia: clinical observations and accelerometric recordings. Rapoport, Nov 473–477

Psychopathology see also specific diagnosis
Is psychopathology in Japan a "black hole"? [letter] Okada, Apr 164
Religiosity and psychopathology [letter]. Markowitz, Sept 414–415

Psychosis
Concurrent use of clozapine and valproate in affective and psychotic disorders. Kando, June 255–257
Treatment of psychosis: resetting the drug cost "thermostat". Reid, Sept suppl B 166–168

Quazepam
Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. Mendels, Feb 60–65

Rating Scales
Measuring response in treatment of depression [letter]. Blum; Preskorn reply, Feb 77

Receptors
Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. Olney, Sept suppl B 43–46

Relapse
Study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Steingard, Nov 470–472

Religion
Religiosity and psychopathology [letter]. Markowitz, Sept 414–415

Risperidone
Efficacy of risperidone on positive features of schizophrenia. McEvoy, May suppl 18–21
Extrapyramidal side effects and tolerability of risperidone: a review. Owens, May suppl 29–35
Introduction. Risperidone: new horizons for the schizophrenic patient. Kane, May suppl 3–4
Negative symptoms in schizophrenia: assessment of the effect of risperidone. Schooler, May suppl 22–28
Pharmacokinetics of risperidone in humans: a summary. Heykants, Apr suppl 13–17
Risperidone: a novel antipsychotic with balanced serotonin- dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Leysen, May suppl 5–12

Romano, John, 1908–1994
John Romano, M.D., 1908–1994. Racy, Sept 379

Schizophrenia
Cerebral morphometry and clozapine treatment in schizophrenia. Bilder, Sept suppl 53–56
Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Osher, Mar 109–113
Diagnostic reassessment and treatment response in schizophrenia. Honer, Dec 528–532

Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? Goldman, Apr 151–153
Effects of clozapine on cognitive function in schizophrenia. Lee, Sept suppl B 82–87
Efficacy of risperidone on positive features of schizophrenia. McEvoy, May suppl 18–21
Enhancing compliance in schizophrenic patients by weekly dosing with levothyroxine sodium [letter]. Walch, Dec 543
Introduction. Risperidone: new horizons for the schizophrenic patient. Kane, May suppl 3–4
Maintenance electroconvulsive therapy in schizophrenia [letter]. Lohr, May 217–218
Negative symptoms in schizophrenia: assessment of the effect of risperidone. Schooler, May suppl 22–28
Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon. Bermanzohn, Nov 488–491
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli, Sept suppl B 94–97
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Potkin, Sept suppl B 133–136
Predictors of clozapine response in schizophrenia. Pickar, Sept suppl B 129–132
Study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Steingard, Nov 470–472

Seasonal Affective Disorder
Mania precipitated by light therapy for patients with SAD [letter]. Chan, Oct 454
Side effects induced by bright light treatment for seasonal affective disorder. Labbate, May 189–191

Sedation
Case report of paradoxical sedation with fluoxetine therapy [letter]. Gupta, Mar 118

Seizures
Antidepressant-associated seizures [letter]. Popli, June 267
Seizures and clozapine dosing schedule [letter]. Chengappa, Oct 456
Seizures associated with clozapine treatment in a state hospital. Wilson, May 184–188
Seizures during clozapine therapy. Devinsky, Sept suppl B 153–156

Self-Injurious Behavior
Harakiri: a clinical study of deliberate self-stabbing. Patel, Mar 98–103

Serotonin
Adverse interaction of cyproheptadine with serotonergic antidepressants [letter]. Katz, July 314–315
Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. Dubovsky, Feb suppl 34–44
Combined SSRI-moclobemide treatment of psychiatric illness. Joffe, Jan 24–25
D_1-,D_2-, and 5-HT_2-receptor occupancy in clozapine-treated patients. Farde, Sept suppl B 67–69
Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Roth, Nov 492–495
Possible therapeutic window for serotonin reuptake inhibitors [letter]. Fichtner; Cain reply, Jan 36–38
Potential benefits of serotonin receptor-specific agents. Sussman, Feb suppl 45–51
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Leysen, May suppl 5–12
Role of 5-HT_1-like receptors in the action of clozapine. Wang, Sept suppl B 23–26
Serotonergic agents and frontal lobe syndrome [letter]. Opler, Aug 362–363
Serotonin reuptake blockers for the treatment of obsessional jealousy. Stein, Jan 30–33
SSRI withdrawal buzz [letter]. Ellison, Dec 544–545
Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? Nierenberg, Sept suppl A 55–61

Sertraline
Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. Rabkin, Oct 433–439
Open trial of sertraline in personality disordered patients with impulsive aggression. Kavoussi, Apr 137–141
Sertraline as a treatment for premature ejaculation [letter]. Wise, Sept 417
Sertraline as the cause of inappropriate antidiuretic hormone secretion [letter]. Llorente, Dec 543–544
Sertraline-induced stuttering [letter]. McCall, July 316

Sexual Function
Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. Gitlin, Sept 406–413
Sertraline as a treatment for premature ejaculation [letter]. Wise, Sept 417

Sexual Obsessions
Sexual obsessions associated with fluoxetine [letter]. Balon, Nov 496

Sexuality
Phenelzine and sexuality [letter]. Warneke; Golwyn reply, May 216–217

SIADH see Antidiuretic Hormone

Sleep
Article questioned [letter]. Landy; Gelenberg reply, Scharf reply, Apr 161–163
Rapid resolution of first episodes of mania: sleep related? Nowlin-Finch, Jan 26–29

Sleep Paralysis
Guy de Maupassant's "The Horla" and sleep paralysis [letter]. Schneck, Dec 544

Social Phobia
Anxiety and growth disturbance: is there a connection? a review of biological studies in social phobia. Uhde, June suppl 17–27
Etiology of social phobia. Rosenbaum, June suppl 10–16
Functional impairment in social phobia. Schneier, Aug 322–331
Introduction. Social phobia: a comprehensive approach to etiology, diagnosis, and treatment. Rosenbaum, June suppl 3–4
Medication therapy for social phobia. Marshall, June suppl 33–37
Paroxetine efficacy in social phobia [letter]. Ringold, Aug 363–364
Social phobia: a clinical overview. Judd, June suppl 5–9
Treatment of social phobia in cognitive-behavioral groups. Heimberg, June suppl 38–46
Treatment of social phobia with benzodiazepines. Davidson, June suppl 28–32

Stimulants
Psychostimulant suppository treatment for depression in the gravely ill [letter]. Holmes, June 265–266

Study Design
Article questioned [letter]. Landy; Gelenberg reply, Scharf reply, Apr 161–163

Stuttering
Sertraline-induced stuttering [letter]. McCall, July 316

Substance Abuse
Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. Sokolski, Sept 380–387
Substance abuse and clozapine treatment. Buckley, Sept suppl B 114–116

Suicide
No harm contract in the emergency assessment of suicidal risk. Stanford, Aug 344–348
Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. Modai, June 252–254
Suicide in major depression in different treatment settings. **Isometsa**, Dec 523–527

Synapses
Pharmacology of antidepressants at the synapse: focus on newer compounds. Richelson, Sept suppl A 34–41

Tardive Dyskinesia
Clozapine in tardive dyskinesia: observations from human and animal model studies. Tamminga, Sept suppl B 102–106

Tardive Oculogyric Crisis
Tardive oculogyric crises with clozapine [letter]. Dave, June 264–265

Thiothixene
Intravenous thiothixene in the agitated patient [letter]. Merkl, Oct 456–457

Tics
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. McDougle, Mar suppl 24–31
Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. Baer, Mar suppl 18–23

Trazodone
Behavioral effects of trazodone in Alzheimer's disease. Lebert, Dec 536–538

Trichotillomania
Trichotillomania and body dysmorphic disorder [letter]. Tanquary; Winchel reply, Jan 35–36

Valproate
Concurrent use of clozapine and valproate in affective and psychotic disorders. Kando, June 255–257
Panic disorder: treatment with valproate. Woodman, Apr 134–136
Valproate pre-treatment for the difficult-to-treat patient with OCD [letter]. Deltito, Nov 500
Valproic acid treatment of episodic explosiveness related to brain injury [letter]. Geracioti Jr, Sept 416–417

Venlafaxine
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer, Mar 104–108
Role of venlafaxine in rational antidepressant therapy. Feighner, Sept suppl A 62–70

Water Imbalance
Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? Goldman, Apr 151–153

Weight
Clozapine and weight gain. Umbricht, Sept suppl B 157–160

Zinc
Zinc salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. Stoll, July 309–311

Zolpidem
Multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. Scharf, May 192–199

Journal of Clinical Psychiatry

Author Index to Volume 55: January 1994 Through December 1994

Abrams BI see Sokolski KN

Agras WS, Rossiter EM, Arnow B, Telch CF, Raeburn SD, Bruce B, Koran LM. One-year follow-up of psychosocial and pharmacologic treatment for bulimia nervosa. May 179–183

Akiskal HS. Dysthymic and cyclothymic depressions: therapeutic considerations. Apr suppl 46–52

Akyol S see Roth A

Alarcon RD. Review of Jacobs D (ed): *Suicide and Clinical Practice.* Apr 165

Albus KE see Piscitelli SC

Allen DM. Review of Bornstein RF:*The Dependent Personality.* Dec 547

Allen DM. Review of Linehan MM: *Cognitive-Behavioral Treatment of Borderline Personality Disorder.* Nov 501–502

Allen DM. Review of Paris J (ed): *Borderline Personality Disorder: Etiology and Treatment.* Sept 418

Allen DM. Review of Silver D, Rosenbluth M (eds): *Handbook of Borderline Disorders.* June 268–269

Allen DM. Review of Yeomans FE, Selzer MA, Clarkin JF: *Treating the Borderline Patient: A Contract-Based Approach.* Nov 501

Allen M see Steingard S

Altman S see Honer WG

Altschuler LL see Nowlin-Finch NL; Hendrick V

Alvir JMJ, Lieberman JA. Agranulocytosis: incidence and risk factors. Sept suppl B 137–138

Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. Sept 394–400

Andreasen NC. Introduction: neuroimaging assessment of cognitive disorders. Nov suppl 3–4

Angst J, Hochstrasser B. Recurrent brief depression: the Zurich study. Apr suppl 3–9

Appleton WS. Reply to Wilson WH: *The Fifth Psychoactive Drug Usage Guide* [letter]. Jan 34–35

Arnow B see Agras WS

Aro HM see Isometsä ET

Aronowitz J see Bilder RM; Safferman AZ

Ashby CR Jr see Wang RY

Ashford JJ see Freeman CP

Ashtari M see Bilder RM

AuBuchon PG, Malatesta VJ. Obsessive compulsive patients with comorbid personality disorder: associated problems and response to a comprehensive behavior therapy. Oct 448–453

Backmund H see Kellner M

Baer L. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. Mar suppl 18–23

Baer L see O'Rourke DA

Baird J see Chengappa KNR

Baird JW see Baker RW

Baker RW, Chengappa KNR, Steingard S, Schooler NR, Baird JW. Reply to LaPorta LD: More on obsessive-compulsive symptoms and clozapine [letter]. July 312

Baker RW see Chengappa KNR

Bakish D see Joffe RT

Balon R. Sexual obsessions associated with fluoxetine [letter]. Nov 496

Balon R. Underutilization of depot neuroleptic therapy [letter with reply]. Jan 39

Banov M see Sachs GS

Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, Kim J-W, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. July 295–300

Barnas C see Hummer M; Stuppaeck CH

Battle AO. Review of Archer RP: *MMPI-A: Assessing Adolescent Psychopathology.* July 318

Battle AO. Review of Gibson HB, Heap M: *Hypnosis in Therapy.* Aug 365

Baxter LR Jr. Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorder. Oct suppl 54–59

Beasley CM Jr. Fluoxetine-dopaminergic interaction data [letter with reply]. Feb 77–78

Beaudett MS see Osher FC

Becker KJ. Review of Foy DW (ed): *Treating PTSD: Cognitive-Behavioral Strategies.* Feb 81

Bellak L, Opler LA. Conceptualizing ADHD [letter with reply]. July 312–313

Benjamin J see Zohar J

Bera R see Potkin SG

Berenson AB see Wagner KD

Berkowitz R see van der Kolk BA

Berman I see Green AI

Bermanzohn PC, Siris SG. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon. Nov 488–491

Bernstein S see Pigott TA

Bertorini TE. Review of Greenberg DA, Aminoff MJ, Simon RP: *Clinical Neurology.* Feb 81

Biederman J see Rosenbaum JF

Biesanz JC see Osher FC

Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA. Cerebral morphometry and clozapine treatment in schizophrenia. Sept suppl B 53–56

Birkett M see Tollefson GD

Blake L see Goldman MB

Bland RC see Weissman MM

Bloom JD see Stanford EJ

Blum MH. Measuring response in treatment of depression [letter with reply]. Feb 77

Bogerts B see Bilder RM

Bourbigot B see Tanneau RS

Boxer PA. Outpatient treatment for "multiple chemical sensitivities" [letter]. July 316

Braun BG see Fichtner CG

Breedlove LR. Review of Reynolds WM (ed): *Internalizing Disorders in Children and Adolescents.* July 318

Breier A. Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. Sept suppl B 122–125

Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. June 249–251

Brown CS. Review of Janicak PG, Davis JM, Preskorn SH, Ayd FJ (eds): *Principles and Practice of Psychopharmacotherapy.* Nov 502

Brown CS. Review of Musa MN: *Pharmacokinetics and Therapeutic Monitoring of Psychiatric Drugs.* Dec 547

Brown JL see Judd LL

Bruce B see Agras WS

Buchsbaum MS see Potkin SG

Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse and clozapine treatment. Sept suppl B 114–116

Bullen JA see Reeves RR

Buller R, Winter P, Ferner U. Efficacy of newer antidepressants [letter with reply]. Nov 499–500

Bunney WE Jr see Potkin SG

Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when

evaluating treatment options for major depressive disorder. Sept suppl A 42–54
Cain JW. Reply to Fichtner CG: Possible therapeutic window for serotonin reuptake inhibitors [letter]. Jan 37–38
Calabrese JR see Kimmel SE
Campeas R see Schneier FR
Canino GJ see Weissman MM
Carreon D see Potkin SG
Castillo J see Kando JC
Ceccherini-Nelli A, Guazzelli M. Treatment of refractory OCD with the dopamine agonist bromocriptine [letter]. Sept 415–416
Centorrino F see Kando JC
Chakos MH see Bilder RM
Chan PKY, Lam RW, Perry KF. Mania precipitated by light therapy for patients with SAD [letter]. Oct 454
Chang Y-J see Potkin SG
Chen J see Gardner EL
Chengappa KNR, Baker RW, Harty I. Seizures and clozapine dosing schedule [letter]. Oct 456
Chengappa KNR, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J. Prevalence of akathisia in patients receiving stable doses of clozapine. Apr 142–145
Chengappa KNR see Baker RW
Christenson GA, Faber RJ, de Zwann M, Raymond NC, Specker SM, Ekern MD, Mackenzie TB, Crosby RD, Crow SJ, Eckert ED, Mussell MP, Mitchell JE. Compulsive buying: descriptive characteristics and psychiatric comorbidity. Jan 5–11
Christenson GA, Faber RJ, Mitchell JE. Reply to Fishbain DA: Do compulsive buyers and kleptomaniacs share identical characteristics? Dec 545–546
Claussen AM see Wilson WH
Coccaro EF see Kavoussi RJ
Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Impact of pregnancy on panic disorder: a case series. July 284–288
Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Postpartum course in women with preexisting panic disorder. July 289–292
Cohen LJ see Hollander E
Cohen SA. Successful clozapine rechallenge following prior intolerance to clozapine [letter]. Nov 498–499
Cohen SA, Underwood MT. Use of clozapine in a mentally retarded and aggressive population. Oct 440–444
Cola PA see Meltzer HY
Cole JO see Banov MD
Collier D see Kerwin RW
Cooper T see Lieberman JA
Cooper TB see Potkin SG
Coplan JD see Tiffon L
Coppen A. Depression as a lethal disease: prevention strategies. Apr suppl 37–45
Corzo D, Yunis JJ, Yunis EJ, Howard A, Lieberman JA. HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. Sept suppl B 149–152
Costa J see Potkin SG
Costa JF see Sokolski KN
Crismon ML see Eggert AE
Crosby RD see Christenson GA
Crow SJ see Christenson GA
Cummings JL see Sokolski KN
Cummings MA, Haviland MG, Wareham JG, Fontana LA. Reply to Swartz CM: Adequate testing of lithium dose prediction [letter]. May 216
Cunningham LA. Depression in the medically ill: choosing an antidepressant. Sept suppl A 90–97
Dave M. Tardive oculogyric crises with clozapine [letter]. June 264–265
Davidson JR, France RD. Bupropion in chronic low back pain [letter]. Aug 362
Davidson JRT, Tupler LA, Potts NLS. Treatment of social phobia with benzodiazepines. June suppl 28–32
Deakin JFW see Freeman CPL
Degreef G see Bilder RM
Delaney J see Chengappa KNR
Del Bene D see Schneier FR
de Leon J, Stanilla JK, White AO, Simpson GM. Anticholinergics to treat clozapine withdrawal [letter]. Mar 119–120
Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. Nov 500
DeMet EM see Sokolski KN
de Moore G see Patel V
Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: a clinical practice survey. Feb 70–76
Deutch AY. Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. Sept suppl B 37–42
DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. Dec suppl 38–45
Devinsky O, Pacia SV. Seizures during clozapine therapy. Sept suppl B 153–156
de Zwann M see Christenson GA
Dimmock JA see Cohen LS
Dixon AK, Huber C, Lowe DA. Clozapine promotes approach-oriented behavior in male mice. Sept suppl B 4–7
Dominguez RA, Mestre SM. Management of treatment-refractory obsessive compulsive disorder patients. Oct suppl 86–92
Dorson PG see Eggert AE
Doty L see Geldmacher DS
Douglas CJ see Wolk SI
Drake RE see Osher FC
Drevets WC. Geriatric depression: brain imaging correlates and pharmacologic considerations. Sept suppl A 71–82
Dreyfuss D see van der Kolk BA
Dror S see Modai I
Dubbert B see Pigott TA
Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. Feb suppl 34–44
Dunner DL. Therapeutic considerations in treating depression in the elderly. Dec suppl 48–58
DuRand CJ see Green AI
Ecker JA see Fontaine R
Eckert ED see Christenson GA
Edwards E see Wang RY
Eggert AE, Crimson ML, Dorson PG. Lack of effect of fluoxetine on plasma clozapine concentrations [letter]. Oct 454–455
Ehmann TS see Honer WG
Eisen JL see Rasmussen SA
Ekern MD see Christenson GA
Elie R see Fontaine R
Elizur A see Rapoport A
Ellison JM. SSRI withdrawal buzz [letter]. Dec 544–545
El-Mallakh RS see Liebowitz NR
Engelhardt CL see Walsh JK
Eppright TD. Review of Greenspan SI: *Infancy and Early Childhood: The Practice of Clinical Assessment and Intervention With Emotional and Developmental Challenges.* Jan 40
Escobar JI see Viner M
Faber RJ see Christenson GA
Fallon BA, Sadik C, Saoud JB, Garfinkel RS. Childhood abuse, family environment, and outcome in bulimia nervosa. Oct 424–428
Fallon BA see Marshall RD; Schneier FR
Faludi G see Fontaine R
Farber NB see Olney JW
Farde L, Nordstrom A-L, Nyberg S, Halldin C, Sedvall G. D_1-, D_2-, and 5-HT_2-receptor occupancy in clozapine treated patients. Sept suppl B 67–69
Fassbender K see Kellner M
Feerick J see Marshall RD
Feighner JP. The role of venlafaxine in rational antidepressant therapy. Sept suppl A 62–70
Feighner J see Schweizer E
Ferguson JM, Mendels J, Manowitz NR. Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. June 258–263
Ferner U see Buller R
Fetrow CW, Hoyt JW, White TM. Clonidine patch: reservoir for abuse [letter]. June 266
Fibiger HC. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. Sept suppl B 33–36
Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors [letter with reply]. Jan 36–37
Figiel GS see Lohr WD
Fishbain DA. Do compulsive buyers and kleptomaniacs share identical characteristics? [letter with reply] Dec 545
Fisler R see van der Kolk BA
Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. Sept suppl B 78–81
Fleischhacker WW see Hummer M; Stuppaeck CH
Fleming F see Miller DD
Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. Double-blind comparison of nefazodone, imipramine, and placebo in major depression. June 234–241
Fontana LA see Cummings MA
Fragala MR see Holmes TF
France RD see Davidson JR
Frazier JA see Piscitelli SC
Freeman CPL, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. July 301–305

Frenkel RE. Review of Hanu Y: *Far Journey: A Psychiatrist's Chronicle.* Oct 458
Friedman G see Potkin SG
Friedman JH. Clozapine treatment of psychosis in patients with Parkinson's disease [letter with reply]. Feb 79
Gaind GS, Rosebush PI, Mazurek MF. Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. Jan 20–23
Gao X-M see Tamminga CA
Gardner EL, Chen J, Paredes W. Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system. Sept suppl B 15–22
Garfinkel R see Schneier FR
Garfinkel RS see Fallon BA
Garo B see Tanneau RS
Geldmacher DS, Waldman AJ, Doty L, Heilman KM. Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. Apr 161
Gelenberg AJ. Editor's note to Landy DA: Article questioned [letter]. Apr 161–163
Gelenberg AJ. *JCP* at mid-decade. Dec 515–516
Genduso L see Tollefson GD
Geracioti TD Jr. Valproic acid treatment of episodic explosiveness related to brain injury [letter]. Sept 416–417
Gerber B see Potkin SG
Gerlach J, Peacock L. Motor and mental side effects of clozapine. Sept suppl B 107–109
Gerlach J see Peacock L
Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. Sept suppl B 139–142
Gill M see Kerwin RW
Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. Sept 406–413
Gitow A see Schneier FR
Glassman AH see Roose SP
Glazer WM, Kane JM. Reply to Balon R: Underutilization of depot neuroleptic therapy [letter]. Jan 39
Gleason R see O'Rourke DA
Goas J-Y see Tanneau RS
Goetz RR see Stanford EJ
Gold DD Jr. Review of Nakazawa T: *Biological Basis of Schizophrenic Disorders.* Aug 365–366
Gold DD Jr. Review of USDHHS: *Outcasts on Main Street: Report of the Federal Task Force on Homelessness and Severe Mental Illness.* July 317
Goldberg TE, Weinberger DR. Effects of clozapine on neurocognition: an overview. Sept suppl B 88–90
Goldman MB, Nash M, Blake L, Petkovic M, Luchins DJ. Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? Apr 151–153
Golwyn DF, Sevlie CP. Reply to Warneke L: Phenelzine and sexuality [letter]. May 217
Goodman WK see McDougle CJ
Gordon CT see Piscitelli SC
Gordon MF see Safferman AZ
Gorelick M see Llorente MD
Gorman JM see Tiffon L
Greden JF. Introduction. New agents for the treatment of depression. Feb suppl 32–33
Green AI, Zalma A, Berman I, DuRand CJ, Salzman C. Clozapine following ECT: a two-step treatment. Sept 388–390
Greenwald S see Weissman MM
Greist JH. Behavior therapy for obsessive compulsive disorder. Oct suppl 60–68
Griffin M see Warner D
Grinshpoon A see Rapoport A
Grothe DR see Piscitelli SC
Grove GA. Cost of HLA typing [letter with replies]. Oct 455
Guazzelli M see Ceccherini-Nelli A
Gulasekaram B see Potkin SG Gullion G, Yeh H-S. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. Sept 401–405
Gullion G, Yeh H-S. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. Sept 401–405
Gupta S, Rajaprabhakaran R. Case report of paradoxical sedation with fluoxetine therapy [letter]. Mar 118
Hales RE see Kunik ME
Halldin C see Farde L
Hamilton MS, Opler LA. Reply to Beasley CM Jr: Fluoxetine-dopaminergic interaction data [letter]. Feb 78–79
Hammerness PG see Pollack MH
Hanks DL see Keller MB
Hanson DR see Roerig JL
Hart RH. Review of Cameron NMdeS: *The New Medicine: Life and Death After Hippocrates.* Oct 458
Harty I see Chengappa KNR
Haviland MG see Cummings MA
Hayes S see Potkin SG
Haykal RF. Review of Greist JH, Jefferson JW: *Depression and Its Treatment, 2nd ed.* Feb 80
Heckelman LR see Schneier FR
Heikkinen ME see Isometsä ET
Heilman KM see Geldmacher DS
Heimberg RG, Juster HR. Treatment of social phobia in cognitive-behavioral groups. June suppl 38–46
Hendrick V, Altshuler LL, Szuba MP. Is there a role for neuroleptics in bipolar depression? Dec 533–535
Henriksson MM see Isometsä ET
Henry A see Tanneau RS
Heykants J, Huang M-L, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. Pharmacokinetics of risperidone in humans: a summary. Apr suppl 13–17
Hindley NJ see Jobst KA
Hirschfeld DR see Rosenbaum JF
Hirschfeld RMA. Guidelines for the long-term treatment of depression. Dec suppl 61–69
Hirschfeld RMA, Holzer CE III. Depressive personality disorder: clinical implications. Apr suppl 10–17
Hochstrasser B see Angst J
Hollander E, Cohen LJ. Assessment and treatment of refractory anxiety. Feb suppl 27–31
Hollander E see Stein DJ
Holman SL see Tollefson GD
Holman TL see Miller DD
Holmes TF, Sabaawi M, Fragala MR. Psychostimulant suppository treatment for depression in the gravely ill [letter]. June 265–266
Holzer CE III see Hirschfeld RMA
Honer WG, Smith GN, MacEwan GW, Kopala L, Altman S, Yorkston N, Ehmann TS, Smith A, Lang M. Diagnostic reassessment and treatment response in schizophrenia. Dec 528–532
Hornig-Rohan M see Amsterdam JD
Houle L see Steiger H
Howard A see Corzo D; Lieberman JA
Howland RH. Biochemical and clinical effects of buspirone augmentation [letter]. June 264
Hoyt JW see Fetrow CW
Hsiao JK see Pickar D
Huang ML see Heykants J
Huber C see Dixon AK
Hudziak JJ see Lohr WD
Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. Clozapine-induced transient white blood count disorders. Oct 429–432
Hummer M see Fleischhacker WW
Hurlbut SC see Osher FC
Hwu H-G see Weissman MM
Isometsä ET, Aro HM, Henriksson MM, Heikkinen ME, Lonnqvist JK. Suicide in major depression in different treatment settings. Dec 523–527
Jackson CW see Brewerton TD
Jagust WJ. Functional imaging in dementia: an overview. Nov suppl 5–11
Jann MW. Nonphysician prescribers [letter]. Sept 414
Janssen PMF see Leysen JE
Jarvis MR see Lohr WD; Rasmussen KG
Jatlow PI see Nelson JC
Jefferson JW, Sen D. Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L. Aug 340–343
Jefferson JW. Reply to Klemfuss H: Potassium supplementation during lithium therapy [letter]. Jan 36
Jeffries JJ see Remington GJ
Jenike MA. Introduction: new developments in the treatment of obsessive compulsive disorders. Oct suppl 3–4
Jenike MA. Overview. OCD: comorbidity and management dilemmas. Mar suppl 3–4
Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. Mar suppl 11–17
Jenike MA see O'Rourke DA
Jin Y see Potkin SG
Jobe TH see Fichtner CG
Jobst KA, Hindley NJ, King E, Smith AD. Diagnosis of Alzheimer's disease: a question of image? Nov suppl 22–31
Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. Jan 24–25
Johns C see Kane JM
Josephson SC see Stein DJ
Judd LL. Social phobia: a clinical overview. June suppl 5–9
Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? Apr suppl 18–28
Judd LL see Zisook S
Juster HR see Heimberg RG
Kafka MP, Prentky RA. Preliminary observations of DSM-III-R Axis I

comorbidity in men with paraphilias and paraphilia-related disorders. Nov 481–487
Kakigi T see Tamminga CA
Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. June 255–257
Kane JM. Introduction. Risperidone: new horizons for the schizophrenic patient. May suppl 3–4
Kane JM, Safferman AZ, Pollack S, Johns C, Szymanski S, Kronig M, Lieberman JA. Clozapine, negative symptoms, and extrapyramidal side effects. Sept suppl B 74–77
Kane JM see Bilder RM; Fleischhacker WW; Glazer WM; Lieberman JA; Safferman AZ; Umbricht DSG
Kaplan Z see Zohar J
Kaplita S see Fontaine R
Karp BI see Vieweg WVR
Kaspi SP see Pollack MH
Katz LS see Sokolski KN
Katz RJ, Rosenthal M. Adverse interaction of cyproheptadine with serotonergic antidepressants [letter]. July 314–315
Kavoussi RJ, Liu J, Coccaro EF. Open trial of sertraline in personality disordered patients with impulsive aggression. Apr 137–141
Keck PE Jr see McElroy SL
Keller MB, Hanks DL. Natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. Sept suppl A 25–33
Kellner M, Fassbender K, Backmund H, Möller A. Familial presenile dementia with motor neuron disease [letter]. Nov 496–497
Kensler TT see Fontaine R
Kerwin RW, Pilowsky L, Munro J, Shaikh S, Gill M, Collier D. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. Sept suppl B 57–62
Kim J-W see Banov MD
Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment-refractory mood disorders. Sept suppl B 91–93
King E see Jobst KA
Kinkead B, Nemeroff CB. Effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Sept suppl B 30–32
Klein DF. Commentary: pregnancy and panic disorder. July 293–294
Klein RG see Pine DS
Klemfuss H. Potassium supplementation during lithium therapy [letter with reply]. Jan 36
Knable MB, Weinberger DR. Limbic-prefrontal connectivity and clozapine. Sept suppl B 70–73
Kolbrener M see Banov MD
Konings SA see Pisciotta AV
Kontras SB. Review of Dalton R, Forman MA: *Psychiatric Hospitalization of School-Age Children.* June 269
Kopala L see Honer WG
Koran L see Tollefson GD
Koran LM see Agras WS
Kronig M see Kane JM
Kronig MH see Lieberman JA
Kunik ME, Yudofsky SC, Silver JM, Hales RE. Pharmacologic approach to management of agitation associated with dementia. Feb suppl 13–17
Kurz M see Fleischhacker WW; Hummer M
Kurzthaler I see Fleischhacker WW
Labbate LA, Lafer B, Thibault A, Sachs GS. Side effects induced by bright light treatment for seasonal affective disorder. May 189–191
Lafer B see Labbate LA; Sachs GS
Lam RW see Chan PKY
Landbloom R see Roerig JL
Landy DA. Article questioned [letter with replies]. Apr 161–163
Landy DA. Reply to Grove GA: Cost of HLA typing [letter]. Oct 455–456
Lang M see Honer WG
LaPorta LD. More on obsessive-compulsive symptoms and clozapine [letter with reply]. July 312
Larocca FEF. Review of Goodman M, Brown J, Dietz P: *Managing Managed Care: A Mental Health Practitioner's Survival Guide.* Sept 419
Lawrence JM. Review of Sadavoy J, Lazarus LW, Jarvik LF (eds): *Comprehensive Review of Geriatric Psychiatry.* June 268
Leadbetter RA, Shutty MS Jr. Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. Sept suppl B 110–113
Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. Dec 536–538
Lee CK see Weissman MM
Lee G. Review of O'Brien ME: *Living With HIV: Experiment in Courage.* Feb 80
Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. Sept suppl B 82–87
Lee SK see Opler LA
Leonard HL see Swedo SE
Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. May suppl 5–12
L'Heureux F see Pigott TA
Lieberman JA, Kane JM, Safferman AZ, Pollack S, Howard A, Szymanski S, Masiar SJ, Kronig MH, Cooper T, Novacenko H. Predictors of response to clozapine. Sept suppl B 126–128
Lieberman JA see Alvir JMJA; Bilder RM; Corzo D; Fleischhacker WW; Kane JM; Safferman AZ
Liebowitz MR see Marshall RD; Schneier FR
Liebowitz NR, El-Mallakh RS. Reply to Rasmussen KG: Asystole in ECT [letter]. July 314
Litman RE see Pickar D
Liu J see Kavoussi RJ
Llorente MD, Gorelick M, Silverman MA. Sertraline as the cause of inappropriate antidiuretic hormone secretion [letter]. Dec 543–544
Lohr WD, Figiel GS, Hudziak JJ, Zorumski CF, Jarvis MR. Maintenance electroconvulsive therapy in schizophrenia [letter]. May 217–218
Lonnqvist JK see Isometsä ET
Lottenberg S see Potkin SG
Lowe DA see Dixon AK
MacEwan GW see Honer WG
Mackenzie TB see Christenson GA
Maislin G see Amsterdam JD
Malatesta VJ see AuBuchon PG
Mandos LA see Schweizer E
Mannens G see Heykants J
Manowitz NR see Ferguson JM
Mareth TR. Hair loss associated with fluoxetine use in two family members [letter]. Apr 163
Markowitz JC. Religiosity and psychopathology [letter]. Sept 414–415
Marshall RD, Schneier FR, Fallon BA, Feerick J, Liebowitz MR. Medication therapy for social phobia. June suppl 33–37
Masiar SJ see Lieberman JA
Mayberg HS. Clinical correlates of PET- and SPECT-identified defects in dementia. Nov suppl 12–21
Mazure CM see Nelson JC
Mazurek MF see Gaind GS
McCall WV. Sertraline-induced stuttering [letter]. July 316
McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. Mar suppl 24–31
McElroy SL, Keck PE Jr, Pope HG Jr, Smith JMR, Strakowski SM. Compulsive buying: a report of 20 cases. June 242–248
McElroy SL, Phillips KA, Keck PE Jr. Obsessive compulsive spectrum disorder. Oct suppl 33–53
McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. May suppl 18–21
McGrath PJ, Stewart JW, Nunes EN, Quitkin FM. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. Aug 336–339
McKenna K see Piscitelli SC
Megens AAHP see Leysen JE
Meglathery SB see Denicoff KD
Meltzer HY. Overview of the mechanism of action of clozapine. Sept suppl B 47–52
Meltzer HY, Cola PA. Pharmacoeconomics of clozapine: a review. Sept suppl B 161–165
Meltzer HY see Buckley P; Kimmel SE; Lee MA; Yamamoto BK
Mendels J. Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. Feb 60–65
Mendels J see Ferguson JM
Merki CO, Miller LJ. Intravenous thiothixene in the agitated patient [letter]. Oct 456–457
Mestre SM see Dominguez RA
Meuldermans W see Heykants J
Michaels M see van der Kolk BA
Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. Sept suppl B 117–121
Miller LJ see Merki CO
Mintz J see Nowlin-Finch NL
Mitchell JE see Christenson GA
Mocquard Y see Tanneau RS
Modai I, Valevski A, Dror S, Weizman A. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. June 252–254
Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. Sept suppl B 27–29

Möller A see Kellner M
Montano CB. Recognition and treatment of depression in a primary care setting. Dec suppl 18–34
Moran M see Tamminga CA
Munro J see Kerwin RW
Murphy DL see Pigott TA
Mussell MP see Christenson GA
Najafi A see Potkin SG
Nash M see Goldman MB
Nelson JC. Initiation of tricyclic treatment at full dose [letter with reply]. June 266–267
Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. Jan 12–19
Nelson JC see Roth A
Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. Dec suppl 3–15
Nemeroff CB see Kinkead B
Nemiah JC. Introduction. When patients don't respond: clinical strategies for managing refractory anxiety and depression. Feb suppl 18–19
Newhouse RG. Review of Klein DF, Wender PH: *Understanding Depression: A Complete Guide to Its Diagnosis and Treatment.* Aug 366
Newman SC see Weissman MM
Nierenberg AA. Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? Sept suppl A 55–61
Nierenberg AA see Phillips KA
Noordsy DL see Osher FC
Nordstrom A-L see Farde L
Northcott CJ, Stein MB. Panic disorder in pregnancy. Dec 539–542
Novacenko H see Lieberman JA
Nowlin-Finch NL, Altschuler LL, Szuba MP, Mintz J. Rapid resolution of first episodes of mania: sleep related? Jan 26–29
Noyes R Jr see Woodman CL
Nunes EN see McGrath PJ
Nyberg S see Farde L
Oakley-Browne MA see Weissman MM
Oepen G see Stoll AL
Okada F. Is psychopathology in Japan a "black hole"? [letter] Apr 164
Oldroyd J see Potkin SG
Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. Sept suppl B 43–46
Ontiveros A see Fontaine R
Opler LA, Ramirez PM, Lee SK. Serotonergic agents and frontal lobe syndrome [letter]. Aug 362–363
Opler LA see Bellak L; Hamilton MS
O'Rourke DA, Wurtman JJ, Wurtman RJ, Tsay R, Gleason R, Baer L, Jenike MA. Aberrant snacking patterns and eating disorders in patients with obsessive compulsive disorder. Oct 445–447
Osher FC, Drake RE, Noordsy DL, Teague GB, Hurlbut SC, Biesanz JC, Beaudett MS. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Mar 109–113
Otto MW see Pollack MH
Owen RR Jr see Pickar D
Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. May suppl 29–35
Pacia SV see Devinsky O
Papp LA see Tiffon L
Paredes W see Gardner EL
Park L see Potkin SG
Parthasarathy R see Vadnal R
Pasquier F see Lebert F
Patel V, de Moore G. Harakiri: a clinical study of deliberate self-stabbing. Mar 98–103
Paulus M see Zisook S
Paulus MP see Judd LL
Peabody CA see Warner D
Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. Feb 44–49
Peacock L see Gerlach J
Pearce PL. Trends in pharmacologic treatment of insomnia [letter with reply]. Apr 163–164
Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. Aug 332–335
Pehek EA see Yamamoto BK
Perry KF see Chan PKY
Perry PJ see Miller DD
Petit H see Lebert F
Petkovic MS see Goldman MB
Pfister GM see Roerig JL
Phillips KA, Nierenberg AA. Assessment and treatment of refractory depression. Feb suppl 20–26
Phillips KA see McElroy SL
Pickar D, Owen RR Jr, Litman RE, Hsiao JK, Su T-P. Predictors of clozapine response in schizophrenia. Sept suppl B 129–132
Pigott TA, L'Heureux F, Dubbert B, Bernstein S, Murphy DL. Obsessive compulsive disorder: comorbid conditions. Oct suppl 15–32
Pilowsky L see Kerwin RW
Pine DS, Klein RG. Reply to Bellak L: Conceptualizing ADHD [letter]. July 313
Pisciotta AV, Konings SA. ^{51}CR release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. Sept suppl B 143–148
Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Sept suppl B 94–97
Plon H see Potkin SG
Plon L see Potkin SG
Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. May 200–205
Pollack S see Bilder RM; Fleischhacker WW; Kane JM; Lieberman JA; Safferman AZ; Umbricht DSG
Pollock RA see Rosenbaum JF
Pope HG Jr see McElroy SL
Popkin MK see Roerig JL
Popli AP, Tanquary J. Antidepressant-associated seizures. June 267
Post RM see Denicoff KD
Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Plon L, Plon H, Park L, Chang Y-J, Oldroyd J, Cooper TB. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Sept suppl B 133–136
Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G, Lottenberg S, Najafi A, Gulasekaram B, Costa J, Richmond GH, Bunney WE Jr. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. Sept suppl B 63–66
Potts NLS see Davidson JRT
Potvin JH see Tollefson GD
Prentky RA see Kafka MP
Preskorn SH. Antidepressant drug selection: criteria and options. Sept suppl A 6–24
Preskorn SH. Introduction: update on antidepressant therapy. Sept suppl A 3–5
Preskorn SH. Reply to Blum MH: Measuring response in treatment of depression [letter]. Feb 77
Preskorn SH see Burke MJ
Price LH see McDougle CJ
Quitkin FM see McGrath PJ
Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. Mar 92–97
Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. Oct 433–439
Rabkin R see Rabkin JG
Racy JC. In memoriam: John Romano, M.D., 1908–1994. Sept 379
Raeburn SD see Agras WS
Rajaprabhakaran R see Gupta S
Ramirez PM see Opler LA
Rapaport MH see Judd LL
Rapoport A, Stein D, Grinshpoon A, Elizur A. Akathisia and pseudoakathisia: clinical observations and accelerometric recordings. Nov 473–477
Rapoport JL see Piscitelli SC
Rasmussen KG, Zorumski CF, Jarvis MR. Asystole in ECT [letter with reply]. July 313–314
Rasmussen SA. Commentary: obsessive compulsive spectrum disorders. Mar 89–91
Rasmussen SA, Eisen JL. Epidemiology and differential diagnosis of obsessive compulsive disorder. Oct suppl 5–14
Rauch SL see Jenike MA
Raymond NC see Christenson GA
Reeves RR, Bullen JA. Misuse of the face-hand test for psychogenic neurologic deficits [letter]. Aug 363
Reid WH. Clinical usefulness of clozapine [letter with reply]. Dec 546
Reid WH. Treatment of psychosis: resetting the drug cost "thermostat". Sept suppl B 166–168
Remington GJ, Jeffries JJ. Erotomanic delusions and electroconvulsive therapy: a case series. July 306–308
Richelson E. Pharmacology of antidepressants at the synapse: focus on newer compounds. Sept suppl A 34–41
Richmond G see Potkin SG
Richmond GH see Potkin SG
Rickels K see Schweizer E
Ringold AL. Paroxetine efficacy in social phobia [letter]. Aug 363–364
Risby ED see Risinger RC
Risch SC see Risinger RC

Risinger RC, Risby ED, Risch SC. Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. May 215
Roberts DL see Fontaine R
Roederer E. Review of GAP report No. 134: *Beyond Symptom Suppression: Improving Long-Term Outcomes in Schizophrenia.* May 220–221
Roerig JL, Hanson DR, Landbloom R, Pfister GM, Popkin MK. Reply to Grove GA: Cost of HLA typing [letter]. Oct 455–456
Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. Sept suppl A 83–89
Rosebush PI see Gaind GS
Rosenbaum JF. Introduction. Social phobia: a comprehensive approach to etiology, diagnosis, and treatment. June suppl 3–4
Rosenbaum JF, Biederman J, Pollock RA, Hirschfeld DR. Etiology of social phobia. June suppl 10–16
Rosenbaum JF see Cohen LS; Pollack MH; Sachs GS
Rosenthal M see Katz RJ
Rosenthal RH. Review of Halmi KA (ed): *Psychobiology and Treatment of Anorexia Nervosa and Bulimia Nervosa.* Sept 418–419
Rossiter EM see Agras WS
Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. Nov 492–495
Roth T see Scharf MB
Rouhart F see Tanneau RS
Rubio-Stipec M see Weissman MM
Sabaawi M see Holmes TF
Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. Double-blind trial of bupropion versus desipramine for bipolar depression. Sept 391–393
Sachs GS see Labbate LA
Sadik C see Fallon BA
Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA. Use of clozapine in neurologic disorders. Sept suppl B 98–101
Safferman AZ see Fleischhacker WW; Kane JM; Lieberman JA
Salcedo MS see Vaz FJ
Salzman C see Green AI
Saoud JB see Fallon BA
Saria A see Hummer M
Sayler ME see Tollefson GD
Saxe G see van der Kolk BA
Scharf MB. Reply to Landy DA: Article questioned [letter]. Apr 161–163
Scharf MB, Roth T, Vogel GW, Walsh JK. Multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. May 192–199
Schlemmer RB see Ziegler DK
Schneck JM. Guy de Maupassant's "The Horla" and sleep paralysis [letter]. Dec 544
Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. Aug 322–331
Schneier FR see Marshall RD
Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. May suppl 22–28
Schooler NR see Baker RW; Chengappa KNR; Steingard S
Schotte A see Leysen JE
Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Mar 104–108
Schwitzer J see Stuppaeck CH
Scialabba D see Banov MD
Scott AM. Review of Barker P: *Basic Family Therapy.* Mar 122
Scott AM. Review of Jack R: *Women and Attempted Suicide.* May 219–220
Scott AM. Review of Katz SE, Nardacci D, Sabatini A (eds): *Intensive Treatment of the Homeless Mentally Ill.* Mar 121
Sedvall G see Farde L
Seelig BJ. Review of Sandler J (ed): *The Harvard Lectures—Anna Freud.* July 317
Sen D see Jefferson JW
Sevlie CP see Golwyn DH
Shahady EJ. Obsessive compulsive disorder in primary care. Oct suppl 79–85
Shaikh S see Kerwin RW
Shelton MD see Chengappa KNR
Shera D see van der Kolk BA
Short DD see Workman EA
Shuchter SR see Zisook S
Shutty MS Jr see Leadbetter RA
Sichel DA see Cohen LS
Silkey B see Burke MJ
Silver JM see Kunik ME
Silverman MA see Llorente MD
Simpson GM see de Leon J
Siris SG see Bermanzohn PC
Sitanggan K see Potkin SG
Sledge PA see Zisook S
Smith A see Honer WG
Smith AD see Jobst KA
Smith GN see Honer WG
Smith JMR see McElroy SL
Snoeck E see Heykants J
Sokolski KN, Cummings JL, Abrams BI, DeMet EM, Katz LS, Costa JF. Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. Sept 380–387
Specker SM see Christenson GA
Stanford EJ, Goetz RR, Bloom JD. No harm contract in the emergency assessment of suicidal risk. Aug 344–348
Stanilla JK see de Leon J
Steiger H, Stotland S, Houle L. Prognostic implications of stable versus transient "borderline features" in bulimic patients. May 206–214
Stein D see Rapoport A
Stein DJ, Hollander E, Josephson SC. Serotonin reuptake blockers for the treatment of obsessional jealousy. Jan 30–33
Stein MB see Northcott CJ
Steingard S. Use of desmopressin to treat clozapine-induced nocturnal enuresis [letter]. July 315–316
Steingard S, Allen M, Schooler NR. Study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Nov 470–472
Steingard S see Baker RW
Stewart JW see McGrath PJ
Stokes TM see Freeman CP
Stoll AL, Oepen G. Zinc salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. July 309–311
Stoll AL see Sachs GS
Stone AB see Pearlstein TB
Stone MH. Review of Sugarman A, Nemiroff RA, Greenson D (eds): *The Technic and Practice of Psychoanalysis, Volume 2.* Feb 80–81
Stotland S see Steiger H
Strakowski SM see McElroy SL
Street L see Schneier FR
Stuppaeck CH, Barnas C, Schwitzer J, Fleischhacker WW. Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. Apr 146–150
Su T-P see Pickar D
Sussman N. Potential benefits of serotonin receptor-specific agents. Feb suppl 45–51
Swartz CM. Adequate testing of lithium dose prediction [letter with reply]. May 215–216
Swedo SE, Leonard HL. Childhood movement disorders and obsessive compulsive disorder. Mar suppl 32–37
Szuba MP see Hendrick V; Nowlin-Finch NL
Szymanski S see Kane JM; Lieberman JA
Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M. Clozapine in tardive dyskinesia: observations from human and animal model studies. Sept suppl B 102–106
Tandeciarz SI see Denicoff KD
Tang C see Potkin SG
Tanneau RS, Henry A, Rouhart F, Bourbigot B, Garo B, Mocquard Y, Goas J-Y. High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. Aug 349–354
Tanquary J. Trichotillomania and body dysmorphic disorder [letter with reply]. Jan 35–36
Tanquary J see Popli AP
Teague GB see Osher FC
Telch CF see Agras WS
Telford J see Potkin SG
Testani M Jr. Clozapine-induced orthostatic hypotension treated with fludrocortisone [letter]. Nov 497–498
Thaker GK see Tamminga CA
Thibault A see Labbate LA
Thibault AB see Sachs GS
Thompson PA see Buckley P; Lee MA
Tiffon L, Coplan JD, Papp LA, Gorman JM. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. Feb 66–69
Tollefson GD, Birkett M, Koran L, Genduso L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Oct suppl 69–78
Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Feb 50–59
Trimble MR see Freeman CPL
Tsay R see O'Rourke DA
Tucker GJ. Introduction. Treatment approaches to anxiety, depression, and aggression in the elderly. Feb suppl 3–4

Tupler LA see Davidson JRT
Uhde TW. Anxiety and growth disturbance: is there a connection? a review of biological studies in social phobia. June suppl 17–27
Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. Sept suppl B 157–160
Underwood MT see Cohen SA
Vadnal R, Parthasarathy R. Review of Kane JM, Lieberman JA (eds): *Adverse Effects of Psychotropic Drugs.* July 318
Valevski A see Modai I
Van Beijsterveldt L see Heykants J
van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. Dec 517–522
Van Peer A see Heykants J
VanValkenburg C. Review of Sher KJ: *Children of Alcoholics: A Critical Appraisal of Theory and Research.* May 220
Vaz FJ, Salcedo MS. Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa [letter]. Mar 118–119
Vieweg WVR. Commentary: treatment strategies in the polydipsia-hyponatremia syndrome. Apr 154–160
Vieweg WVR, Karp BI. Commentary: severe hyponatremia in the polydipsia-hyponatremia syndrome. Aug 355–361
Viner MW, Escobar JI. Apparent neurotoxicity associated with clozapine [letter]. Jan 38–39
Vogel GW see Scharf MB
Wagner G see Rabkin JG
Wagner KD, Berenson AB. Norplant-associated major depression and panic disorder. Nov 478–480
Walch TJ. Enhancing compliance in schizophrenic patients by weekly dosing with levothyroxine sodium [letter]. Dec 543
Waldman AJ see Geldmacher DS
Walker PW. Review of Coffey CE (ed): *The Clinical Science of Electroconvulsive Therapy.* Sept 419
Walsh JK, Engelhardt CL. Reply to Pearce PL: Trends in pharmacologic treatment of insomnia [letter]. Apr 164
Walsh JK see Scharf MB
Wang RY, Ashby CR Jr, Edwards E, Zhang JY. Role of 5-HT_3-like receptors in the action of clozapine. Sept suppl B 23–26
Wareham JG see Cummings MA
Warneke L. Phenelzine and sexuality [letter with reply]. May 216–217
Warner D, Griffin M, Peabody CA. Reply to Nelson JC: Initiation of tricyclic treatment at full dose [letter]. June 267
Way L see Buckley P
Weinberger DR see Knable MB; Goldberg TE
Weiss KJ. Management of anxiety and depression syndromes in the elderly. Feb suppl 5–12
Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu H-G, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, Wittchen H-U, Yeh E-K. Cross national epidemiology of obsessive compulsive disorder. Mar suppl 5–10
Weizman A see Modai I
White AO see de Leon J
White TM see Fetrow CW
Wickramaratne PJ see Weissman MM
Wilson WH. Reply to Reid WH: Clinical usefulness of clozapine [letter]. Dec 546
Wilson WH. *The Fifth Psychoactive Drug Usage Guide* [letter with reply]. Jan 34
Wilson WH, Claussen AM. Seizures associated with clozapine treatment in a state hospital. May 184–188
Winchel RM. Reply to Tanquary J: Trichotillomania and body dysmorphic disorder [letter]. Jan 35–36
Wines JD Jr see Banov MD
Winter P see Buller R
Wise TN. Sertraline as a treatment for premature ejaculation [letter]. Sept 417
Wittchen H-U see Weissman MM
Woestenborghs R see Heykants J
Wolk SI, Douglas CJ. Reply to Friedman JH: Clozapine treatment of psychosis in patients with Parkinson's disease [letter]. Feb 79
Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. Apr 134–136
Workman EA, Short DD. Reply to Buller R: Efficacy of newer antidepressants [letter]. Nov 499–500
Woyshville MJ see Kimmel SE
Wu H see Bilder RM
Wurtman JJ see O'Rourke DA
Wurtman RJ see O'Rourke DA
Yamamoto BK, Pehek EA, Meltzer HY. Brain region effects of clozapine on amino acid and monoamine transmission. Sept suppl B 8–14
Yeh E-K see Weissman MM
Yeh H-S see Gullion GR
Yorkston N see Honer WG
Yudofsky SC see Kunik ME
Yunis EJ see Corzo D
Yunis JJ see Corzo D
Zalma A see Green AI
Zarate CA Jr see Banov MD
Zhang JY see Wang RY
Ziegler DK, Schlemmer RB. Familial psychogenic blindness and headache: a case study. Mar 114–117
Zisook S, Shuchter SR, Sledge PA, Paulus M, Judd LL. Spectrum of depressive phenomena after spousal bereavement. Apr suppl 29–36
Zohar J, Kaplan Z, Benjamin J. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. Mar 86–88
Zorumski CF see Lohr WD; Rasmussen KG

Writing Support Services Available

Now available from Physicians Postgraduate Press, Inc., is its "Author's Direct Service." Our staff of experts are available to help you write manuscripts, create slide presentations, or provide professional editorial assistance for any project you may undertake.

For further information, please contact Ms. Judy Beach, Medical Resources Division, Physicians Postgraduate Press, Inc., P.O. Box 240008, Memphis, TN 38124.